As of March 23, 2026, Larimar Therapeutics's top three insider holders are Thomas Edward Hamilton (Director, 664.80K shares), Carole Ben-Maimon (President And Ceo, 368.28K shares), Michael Celano (Chief Financial Officer, 215.78K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Thomas Edward Hamilton | 664,798 | 0 | 02 Mar, 2026 | |
| Carole Ben-Maimon | President And Ceo | 368,276 | 0 | 27 Jan, 2026 |
| Michael Celano | Chief Financial Officer | 215,785 | 0 | 27 Jan, 2026 |
| Gopi Shankar | Chief Development Officer | 76,443 | 0 | 27 Jan, 2026 |
| Russell Clayton | Chief Medical Officer | 71,443 | 0 | 27 Jan, 2026 |
| Frank E Thomas | 7,000 | 0 | 02 Mar, 2026 | |
| Jeffrey W Sherman | 5,000 | 0 | 02 Mar, 2026 | |
| Joseph Truitt | 2,750 | 0 | 18 May, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 27 Feb, 2026 | Thomas Edward Hamilton | Common Stock | A | 100,000 | $5.00 | 664,798 | D | P |
| 27 Feb, 2026 | Jeffrey W Sherman | Common Stock | A | 5,000 | $5.00 | 5,000 | D | P |
| 27 Feb, 2026 | Frank E Thomas | Common Stock | A | 5,000 | $5.00 | 7,000 | D | P |
| 26 Jan, 2026 | Michael Celano | Common Stock | A | 37,604 | $0.00 | 215,785 | D | A |
| 26 Jan, 2026 | Gopi Shankar | Common Stock | A | 25,637 | $0.00 | 76,443 | D | A |
| 26 Jan, 2026 | Carole Ben-Maimon | Common Stock | A | 100,100 | $0.00 | 368,276 | D | A |
| 26 Jan, 2026 | Russell Clayton | Common Stock | A | 25,637 | $0.00 | 71,443 | D | A |
| 26 Jan, 2026 | Michael Celano | Stock Option (Right to Buy) | A | 225,622 | $0.00 | 225,622 | D | A |
| 26 Jan, 2026 | Russell Clayton | Stock Option (Right to Buy) | A | 153,822 | $0.00 | 153,822 | D | A |
| 26 Jan, 2026 | Gopi Shankar | Stock Option (Right to Buy) | A | 153,822 | $0.00 | 153,822 | D | A |
| 26 Jan, 2026 | Carole Ben-Maimon | Stock Option (Right to Buy) | A | 600,600 | $0.00 | 600,600 | D | A |
| 13 May, 2025 | Jeffrey W Sherman | Stock Option (Right to Buy) | A | 19,000 | $0.00 | 19,000 | D | A |
| 13 May, 2025 | Joseph Truitt | Stock Option (Right to Buy) | A | 19,000 | $0.00 | 19,000 | D | A |
| 13 May, 2025 | Frank E Thomas | Stock Option (Right to Buy) | A | 19,000 | $0.00 | 19,000 | D | A |
| 13 May, 2025 | Thomas Edward Hamilton | Stock Option (Right to Buy) | A | 19,000 | $0.00 | 19,000 | D | A |
| 22 Jan, 2025 | Carole Ben-Maimon | Common Stock | A | 91,000 | $0.00 | 387,208 | D | A |
| 22 Jan, 2025 | Michael Celano | Common Stock | A | 34,185 | $0.00 | 178,181 | D | A |
| 22 Jan, 2025 | Gopi Shankar | Common Stock | A | 23,306 | $0.00 | 50,806 | D | A |
| 22 Jan, 2025 | Russell Clayton | Common Stock | A | 23,306 | $0.00 | 45,806 | D | A |
| 22 Jan, 2025 | Michael Celano | Stock Option (Right to Buy) | A | 205,111 | $0.00 | 205,111 | D | A |